文献速递皮肤肿瘤

基底细胞癌干预措施:Cochrane系统评价简版与GRADE评估

Interventions for basal cell carcinoma: abridged Cochrane systematic review and GRADE assessments.
PubMed 文献 · Br J Dermatol · 2021-05-05

结果显示手术干预复发率最低,莫氏显微手术较手术切除可能略减少面部原发性高危基底细胞癌复发(低确定性证据);非手术治疗对低风险基底细胞癌效果不及手术但复发率可接受且美容效果可能更优。

要点

  • 手术干预复发率最低,仍是高危基底细胞癌的金标准。
  • 莫氏显微手术较手术切除可能略减少面部原发性高危基底细胞癌复发。
  • 低风险基底细胞癌非手术治疗中,局部咪喹莫特证据最充分。

核心结论

  • 手术干预复发率较低,仍是高危基底细胞癌的金标准。
  • 非手术治疗中,局部咪喹莫特对低风险基底细胞癌疗效证据最充分。

研究设计与样本

  • 纳入52项随机对照试验,共6990例免疫正常成人原发性基底细胞癌患者,中位年龄65岁(范围20-95)。
  • 采用GRADE方法评估证据确定性,并使用Cochrane标准方法学程序。

主要发现

  • 总体手术干预复发率最低。
  • 对于原发性面部基底细胞癌(高危组织学亚型或位于H区或两者兼有),莫氏显微手术较手术切除可能略减少复发(低确定性证据)。
  • 非手术治疗用于低风险基底细胞癌时效果不及手术,但复发率可接受且美容效果可能更优。
  • 感兴趣结局的证据确定性主要为低或中等。

关键数值与推荐

  • 手术干预复发率最低,为高危基底细胞癌的金标准。
  • 莫氏显微手术较手术切除可能略减少原发性面部高危基底细胞癌复发(低确定性证据)。
  • 低风险基底细胞癌非手术治疗复发率可接受且美容效果可能更优。
  • 局部咪喹莫特在非手术治疗中疗效证据最充分。

临床怎么用

  • 高危基底细胞癌应优先选择手术干预。
  • 原发性面部高危基底细胞癌可考虑莫氏显微手术以可能降低复发。
  • 低风险基底细胞癌可选择非手术治疗,局部咪喹莫特证据最充分,但需告知复发率可能高于手术。

局限性

  • 感兴趣结局的证据确定性主要为低或中等。
  • 未来研究需统一核心结局指标并延长随访时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer affecting white-skinned individuals, and the worldwide incidence is increasing. Although rarely fatal, BCC is associated with significant morbidity and costs. OBJECTIVES: To assess the effects of interventions for primary BCC in immunocompetent adults. METHODS: We updated our searches of the following databases to November 2019: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL and LILACS. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation method. We used standard methodological procedures expected by Cochrane. RESULTS: We included 52 randomized controlled trials with 6990 participants (median age 65 years; range 20-95). Mean study duration was 13 months (range 6 weeks-10 years). Ninety-two per cent (n = 48/52) of studies exclusively included histologically low-risk BCC (nodular and superficial subtypes). The certainty of evidence was predominantly low or moderate for the outcomes of interest. Overall, surgical interventions have the lowest recurrence rates, and there may be slightly fewer recurrences with Mohs micrographic surgery over surgical excision for primary, facial BCC (high-risk histological subtype or located in the 'H-zone' or both) (low-certainty evidence). Nonsurgical treatments, when used for low-risk BCC, are less effective than surgical treatments, but recurrence rates are acceptable and cosmetic outcomes are probably superior. CONCLUSIONS: Surgical interventions have lower recurrence rates and remain the gold standard for high-risk BCC. Of the nonsurgical treatments, topical imiquimod has the best evidence to support its efficacy for low-risk BCC. Priorities for future research include agreement on core outcome measures and studies with longer follow-up.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Thomson J, Hogan S, Leonardi-Bee J, et al. Interventions for basal cell carcinoma: abridged Cochrane systematic review and GRADE assessments. Br J Dermatol. 2021. PMID: 33448328. doi:10.1111/bjd.19809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。